Previous close | 12.09 |
Open | 12.13 |
Bid | 11.81 x 100 |
Ask | 11.84 x 100 |
Day's range | 11.70 - 12.13 |
52-week range | 10.87 - 83.60 |
Volume | |
Avg. volume | 1,279,367 |
Market cap | 1.267B |
Beta (5Y monthly) | 0.43 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NovoCure (NVCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Novocure stock surged Wednesday after its medtech device nearly doubled the length of time patients with brain tumors lived before worsening.